SAN DIEGO and SUZHOU, China, April 07, 2025 — Adagene Inc. (Nasdaq: ADAG), a company dedicated to revolutionizing antibody-based therapy discovery and development, announced today that its Chairman, CEO, and President of R&D, Peter Luo, Ph.D., will be engaging in one-on-one meetings with investors and delivering a corporate update at Stifel’s 2025 Virtual Targeted Oncology Forum, scheduled for April 8-9.
Stifel’s 2025 Virtual Targeted Oncology Forum
- Presentation Date: Tuesday, April 8
- Presentation Time: 12:30-12:55 PM (Eastern Time)
- Location: Virtual
A replay of the presentation via webcast will be available for at least 30 days in the section of Adagene’s website at .
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a clinical-stage, platform-driven biotech firm focused on transforming the landscape of cancer immunotherapy through innovative antibody-based therapies. Utilizing computational biology and AI, Adagene designs novel antibodies to address unmet global patient needs and has established strategic partnerships leveraging its SAFEbody® precision masking technology across diverse scientific approaches.
Adagene’s highly differentiated pipeline, fueled by its Dynamic Precision Library (DPL) platform—comprising NEObody™, SAFEbody, and POWERbody™ technologies—features novel immunotherapy programs. The SAFEbody technology enhances safety and tolerability of antibody therapeutics by using precision masking to shield the biologic therapy’s binding domain. Activation within the tumor microenvironment enables tumor-specific targeting of antibodies, minimizing off-target toxicity in healthy tissues.
ADG126 (muzastotug), Adagene’s leading clinical program, is a masked, anti-CTLA-4 SAFEbody targeting a specific CTLA-4 epitope in regulatory T cells (Tregs) within the tumor microenvironment. Currently, ADG126 is undergoing phase 1b/2 clinical trials in combination with anti-PD-1 therapy, with a focus on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Clinical research validates the SAFEbody platform’s applicability to various antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For additional details, please visit .
Connect with Adagene on , and .
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
Bruce Mackle
LifeSci Advisors
